{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"<84 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"≥84 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Duration of SD, was defined as the number of days between the date of the first dose of treatment and the first date of disease progression or death.\n\nSD was regarded as durable if, after observing SD, the first observation of progression disease was at least 84 days after the start of study treatment.","groups":[{"description":"A dose of 60 mg/m2 administered over 60 minutes on D1 and D15 of 4-week cycles","id":"OG000","title":"Tinostamustine (EDO-S101) - Sub Study 1 (SS1)"},{"description":"A dose of 80 mg/m2 administered over 80 minutes on D1 and D15 of 4-week cycles.","id":"OG001","title":"Tinostamustine (EDO-S101) - Sub Study 2 (SS2)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis population includes only those subjects who achieved stable disease (SD). The Duration of SD (was regarded as durable if, after observing SD, the first observation of PD was at least 84 days after the start of study treatment) was based of number of patients with Best Overall Stable Disease Response.","reportingStatus":"POSTED","timeFrame":"From start of treatment, assessed every 2 cycles, until first documented complete CR, PR or SD, up to 6 months. If SD, assessment continued every 2 cycles until CR/PR/death (up to 6 months).","title":"Number of Participants With Duration of Stable Disease (SD) That Persists for at Least 4 Months in Selected Solid Tumor Cohorts in Sub Studies.","type":"SECONDARY","unitOfMeasure":"Participants"}